Individualized Treosulfan-Based Conditioning Improves Outcomes of Allogeneic Hematopoietic Transplantation for Myelodysplastic Syndrome: A 25-Year Retrospective, Population-Based Analysis
• Allo-HCT conditioning in MDS shifts toward reduced toxicity and broader eligibility • FluTreo have improved survival by lowering NRM without increasing relapse • Treosulfan dose-adjustment appears to mitigate comorbidity-related risk
Authors
- Kirsten Grønbæk (ORCID: https://orcid.org/0000-0002-1535-9601)
- Morten Orebo Holmström (ORCID: https://orcid.org/0000-0002-3764-8578)
- Duruta Weber (ORCID: https://orcid.org/0000-0002-0442-7023)
- Eileen Wedge (ORCID: https://orcid.org/0000-0003-3756-6094)
- Brian Kornblit
- Henrik Sengeløv (ORCID: https://orcid.org/0000-0002-5991-2958)
- Marietta Nygaard (ORCID: https://orcid.org/0000-0002-8339-8899)
- Bo Kok Mortensen
- Ida Schjødt
- Niels Smedegaard Andersen
- Søren Lykke Petersen
- Lone Smidstrup Friis
- Johanne Skovgaard Schovsbo
Institutions
- Odense University Hospital (DK)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
Publication Details
- Journal
- Transplantation and Cellular Therapy
- Published
- 2025-11-28
- DOI
- https://doi.org/10.1016/j.jtct.2025.11.030
- Primary Topic
- Acute Myeloid Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Rigshospitalet